Summarizing the state of the art regarding clinical trials in which GM-CSF has been used as an adjuvant in many different clinical trial settings in melanoma patients, Hoeller noted that evidence for clinical efficacy of GM-CSF is controversial and that the optimal treatment regimen and effectiveness of such treatment in patients with advanced melanoma has to be worked out [42]. The gene discussed is CSF2; the disease is melanoma.